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Abstract
Background: Cathepsins represent a group of proteases involved in determining the metastatic potential of cancer
cells. Among these are cysteinyl- (e.g. cathepsin B and cathepsin L) and aspartyl-proteases (e.g. cathepsin D),
normally present inside the lysosomes as inactive proenzymes. Once released in the extracellular space, cathepsins
contribute to metastatic potential by facilitating cell migration and invasiveness.
Results: In the present work we first evaluated, by in vitro procedures, the role of cathepsins B, L and D, in the
remodeling, spreading and invasiveness of eight different cell lines: four primary and four metastatic melanoma cell
lines. Among these, we considered two cell lines derived from a primary cutaneous melanoma and from a
supraclavicular lymph node metastasis of the same patient. To this purpose, the effects of specific chemical
inhibitors of these proteases, i.e. CA-074 and CA-074Me for cathepsin B, Cathepsin inhibitor II for cathepsin L, and
Pepstatin A for cathepsin D, were evaluated. In addition, we also analyzed the effects of the biological inhibitors of
these cathepsins, i.e. specific antibodies, on cell invasiveness. We found that i) cathepsin B, but not cathepsins L
and D, was highly expressed at the surface of metastatic but not of primary melanoma cell lines and that ii) CA-
074, or specific antibodies to cathepsin B, hindered metastatic cell spreading and dissemination, whereas neither
chemical nor biological inhibitors of cathepsins D and L had significant effects. Accordingly, in vivo studies, i.e. in
murine xenografts, demonstrated that CA-074 significantly reduced human melanoma growth and the number of
artificial lung metastases.
Conclusions: These results suggest a reappraisal of the use of cathepsin B inhibitors (either chemical or biological)
as innovative strategy in the management of metastatic melanoma disease.
Background
Cathepsins are a large family of cysteinyl-, aspartyl- and
serine-proteases composed of at least twelve different
molecules, which are distinguished by their structure,
catalytic mechanism, and substrate specificity [1,2]. They
are normally found inside the cell and appear commonly
sequestered in well-defined organelles, mainly lyso-
somes, as inactive proenzymes [3]. When cathepsins are
released outside the cell and activated, they trigger the
degradation of the constituents of the extracellular
matrix and basement membrane, such as type IV col-
lagen, fibronectin, and laminin [4]. Their proteolytic
activity has been suggested as a key factor in determin-
ing the metastatic potential of cancer cells [5]. Indeed,
either cysteinyl- or aspartyl-proteases, by degrading the
extracellular matrix, can directly contribute to cell
migration and invasiveness, at least by dissolving the
physical barriers limiting cell movements and spreading
[for a review see [6]]. Among the members of this
family of proteases, cathepsins B, D, K and L are
hypothesized to play a major role [7,8].
Cutaneous melanoma arises from melanocytes and
represents the most aggressive form of skin cancer. As
for other cancers, melanoma progression is believed to
depend upon a series of increasing survival-oriented
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generate a more malignant phenotype. The ultimate
result of this process is the development of cancer cell
clones selected for their ability to survive in extremely
unfavorable microenvironmental conditions and capable
of overwhelm the lack of nutrients and the deficiency of
metabolic products. Indeed, despite chemo- and radio-
therapeutic treatments, these cells can deceive host’s
immune response, survive hypoxia, oxidative stress,
induction of apoptosis, and ultimately develop a remark-
able propensity for metastatic spreading, the most life-
threatening event in melanoma patients [9]. The key
role of cathepsins in metastatic melanoma progression
has been investigated in several experimental and clini-
cal studies, where overexpression of cathepsins was
associated with a worse prognosis and high cancer disse-
mination [10-13].
In the present work we investigated in both in vitro
and in vivo systems the effects of cathepsin B, D and L
i n h i b i t o r s ,i . e .c h e m i c a la n dbiological (e.g. antibodies)
in modulating metastatic melanoma cells invasiveness.
We found that, unlike cathepsins D and L, the inhibition
of cathepsin B significantly impaired cell invasiveness
and metastatic potential.
Materials and methods
Melanoma cell cultures and in vitro treatments
The HLA-A2 1B6 (indicated as PM1 throughout the
paper) and 8863 (indicated as MM1 throughout the
paper) melanoma cell lines were obtained as previously
reported [14-16]. The LP (PM2) cell line derived from a
primary cutaneous melanoma (Clark’s level V; Breslow
12 mm), while the LM cell line (MM2) from a supracla-
vicular lymph node metastasis of the same patient [17].
Other human melanoma cells used (PM3 and PM4 and
MM3) were obtained from melanomas (primary or
metastatic, respectively) of patients surgically resected at
the Istituto Nazionale dei Tumori, Milan, Italy. Human
M20 melanoma cell line (MM4) was obtained as
reported [18]. All cell lines were cultivated at 37°C in
5% CO2 atmosphere in RPMI-1640 supplemented with
50 U/ml penicillin, 50 mg/ml streptomycin (BioWhit-
taker, Verviers, Belgium) and 10% FCS (Sebam, Berlin,
Germany). For cell migration and invasion assays, cells
were seeded in the presence of the cathepsin D inhibitor
(Pepstatin A, 100 μM, Calbiochem), the cathepsin L
inhibitor (cathepsin L inhibitor II, Z-FY-CHO, 10 μM,
Calbiochem) as well as two cathepsin B inhibitors: CA-
074 (cell unpermeant) and CA-074Me (cell permeant)
(both given at a concentration of 10 μM, Calbiochem,
Nottingham, UK). Since these two inhibitors gave simi-
lar results, i.e. not-significant differences were detected
in all the experimental conditions considered here, only
the results obtained with the CA-074 will be reported.
Cells treated with the same concentration of the solvent
(DMSO) were considered as control. Alternatively to
these synthetic inhibitors, cells were also incubated with
specific antibodies to cathepsin B, D (both Calbiochem)
or L (Alexis) (60 μg/ml). Cells treated with the same
concentration of IgG were considered as control.
Relative quantification of procatepsin B gene expression
by real-time RT-PCR
One-step quantitative RT-PCR analysis for procathepsin
B and cyclophilin A expression was performed as
described [19]. Quantitative RT-PCR for cyclophilin A
was carried out on each sample as an internal control
for template levels.
Primer sequences for procathepsin B:
FW: 5′- GATCATGTGGCAGCTCTGGGCCTCC
CTCTG -3′;
RV: 5′- GTCTTAGATCTTTTCCCAGTACTGATC
GG -3′.
Primer sequences for cyclophilin A:
FW: 5′-TGGTCAACCCCACCGTGTTC-3′;
RV: 5′-GCCATCCAACCACTCAGTC-3′.
Primer sequences were obtained from the NCBI data-
base (GenBank accession number E10341.1 and
BC000689, respectively).The relative expression of
human procathepsin B mRNA was calculated as
described [20].
Analysis of lysosomal compartment
For evaluation of lysosomal acidity and volume, cells
were stained with 1 μM LysoSensor probe or Lyso-
Tracker probe, respectively for 5 min (LysoSensor) or
15 min (LysoTracker) at 37°C and immediately analyzed
by a cytometer. Comparisons among different melanoma
cell lines (either primary or metastatic) were conducted
by CellQuest Software using the median values of fluor-
escence intensity histograms as previously described
[21].
Survival in acidic microenvironment
Primary and metastatic melanoma cell lines were seeded
in RPMI 1640 with 10% FCS at pH values of 7.4 or 5.5,
as previously described. The pH value of 5.5 was
obtained by adding 2 N HCl to the RPMI 1640 culture
medium [21]. After 5 day in culture, cells were stained
with 0.4% Trypan blue and analyzed by flow cytometry.
Expression of cathepsins B, D and L and cystatin C
Total amount of cathepsin B and D and L were evalu-
ated by Western blot as previously reported [22]. Cell
surface cathepsin B and D and L were detected by flow
cytometry in unfixed living cells stained with specific
primary antibodies (for cathepsin B and D, polyclonal
antibody Calbiochem; for cathepsin L, monoclonal
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After washings, cells were incubated for additional 30
min with a secondary Alexa-488-conjugated anti-rabbit
or anti-mouse antibody (Molecular Probes, Eugene, OR,
USA). Cells were analyzed on a cytometer or, alterna-
tively, were fixed for 10 min in 4% paraformaldehyde
and observed with a Nikon Microphot fluorescence
microscope. Images were captured by a color chilled 3
charge-coupled device (CCD) camera (Hamamatsu,
Japan) and analyzed by the OPTILAB (Graftek, France)
software. For evaluation of cystatin C expression level,
fixed cells were permeabilized and then stained with
specific monoclonal antibody against cystatin C (10 μg/
ml, Abcam Ltd.21 Cambridge, UK) as previously
reported for other intracellular antigens [22]. Samples
were analyzed on a FACScan flow cytometer (Becton
Dickinson, San Jose’, CA, USA) by using FL-1 detector.
Assay for activity of cathepsins
Cathepsin B and D and L activity in the cell medium
were evaluated by using sensitive fluorogenic substrates:
Abz-Gly-Ile-Val-Arg~Ala-Lys(Dnp)-OH (Ex: 320; Em:
420), D Bz-Arg-Gly-Phe-Phe-Pro-4MeObNA, HCl (Ex:
345; Em: 425) and Ac-His-Arg-Tyr-Arg-ACC (Ex:380;
Em: 460) specific for cathepsin B, D and L, respectively
(all Calbiochem) as previously reported [23]. Fluores-
cence of the samples (in triplicate for each experimental
condition) was read by using a microplate fluorometer.
Cystatin C and VEGF-A evaluation in the culture medium
Evaluation of cystatin C and vascular endothelial growth
factor A (VEGF-A) in cell culture medium was per-
formed with specific ELISA kits from Alexis and Bender
MedSystem (Lausen, Switzerland), respectively. Accord-
ing to the manufacturer instructions, medium samples
were analyzed by a plate microreader with 450 ± 10 nm
filter. Detected values were compared with a standard
curve and reported as ng/ml (cystatin C) or pg/ml
(VEGF-A).
Cell invasion assays
Tumor cell invasion was determined in vitro by using
transwell culture inserts (8.0-μm pore size) coated with
Matrigel (Becton Dickinson) as previously reported [24].
Each assay was carried out at least three times in tripli-
cate for each experimental condition. To determine
cathepsin B surface amount, cells on the filter top or
migrating to the bottom surface of the filter were har-
vested and stained as reported above.
Cathepsin B gene silencing with siRNA
Melanoma cells were cultured in antibiotic-free medium
and transfected with Dharma FECT 4 reagent (Dharma-
con, Lafayette, CO), according to the manufacturer’s
instructions, using 100 nM siRNA human cathepsin B,
D and L. The transfection efficiency was confirmed by
using a Dharmacon’s positive silencing control, siGLO
laminin A/C siRNA. After 24 h, the culture medium
was replaced with fresh medium and transfected again,
as above, with 100 nM siRNA. The siRNAs targeting
human cathepsins were the following. For cathepsin B: r
(GGAUCACUGCGGAAUCGAA)dTdT and r(UUC-
GAUUCCGCAGUGAUCC)dTdG; for cathepsin D: r
(AAGUGGUGGACCAGAACAUC)dTdG and for cathe-
psin L: 5′-GGCGATGCACAACAGATTATT-3′.A f t e r
further 48 h, the effect of transfection on protein
expression was verified by Western blot or flow cytome-
try analyses. Cells knocked down for cathepsins were
then tested for their invasion capability.
In vivo experiments
CD-1 male nude (nu/nu) mice, 6-8 weeks old and
weighing 22-24 g were purchased from Charles River
Laboratories (Calco, Italy). All procedures involving ani-
mals and their care were in accordance with institu-
tional guidelines under the control of the Italian
Ministry of Public Health (guided by International
Guideline Principles for Biomedical Research Involving
Animals developed by the Council for International
Organization of Medical Sciences). To study the effect
of CA-074 on the growth of MM1 human melanoma,
cells in exponential phase of in vitro growth were
injected into the hind leg muscles of mice at 5 × 10
6
cells/mouse. Mice were treated as from day 6 after
tumor implant when a tumor mass of about 250 mg
was evident, by injecting CA-074 i.v. at 10 mg/kg for
eight consecutive days. This dose was chosen based on
previous results [25] and on our preliminary experi-
ments showing the tolerability of the treatment on
healthy mice. Control animals received vehicle alone.
Tumor weight was calculated by caliper measurements
as previously reported [26]. Antitumor efficacy of treat-
ments was assessed by the following end-points: a) per-
cent tumor weight inhibition, calculated as [1-(mean
tumor weight of treated mice/mean tumor weight of
controls)] x 100; b) tumor growth delay, evaluated com-
paring the median times for treated and untreated
tumors, respectively, to achieve equivalent size. To eval-
uate the antimetastatic efficacy of CA-074, MM4 cells
were injected i.v. at 5 × 10
4 cells/mouse. The day after
treatment the drug was administered i.v. by using the
same schedule reported above. Control animals were
injected with vehicle alone. Two weeks after the injec-
tion of cells, mice were killed, their lungs removed and
fixed in Bouin’s solution to distinguish tumor nodules
from lung tissue, and the number of metastases was
determined under a stereomicroscope. The efficacy of
treatment was assessed by comparing the reduction in
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mice. Each experimental group consisted of six mice.
Data analysis and statistics
All samples were analyzed with a FACScan cytometer
(Becton Dickinson) equipped with a 488 argon laser. At
least 20,000 events were acquired. The expression level
of the analyzed proteins was expressed as a median
value of the fluorescence emission curve. Statistical sig-
nificance among different experimental conditions of
the same experiment was calculated by using the para-
metric Kolmogorov-Smirnov (K/S) test. Statistical analy-
sis among different experiments was performed by
Student’s t-test by using Statview program for Macin-
tosh. All data reported were verified at least in three
independent experiments and expressed as mean ± stan-
dard deviation (SD). Only p values of less than 0.01
were considered as statistically significant.
Results
Expression of cathepsins in cells from primary and
metastatic human melanomas
We analyzed the total amount of cathepsin B, D and L
in four cell lines derived from human metastatic mela-
nomas (MM1-MM4) and in four cell lines derived from
primary lesions (PM1-PM4) by means of Western blot-
ting. It appeared evident that the amount of cathepsin B
resulted higher in cells from primary melanomas rather
than in those from metastatic ones. This is shown in
Figure 1A and 1B (in which two representative primary
and two metastatic melanoma cell lines are shown) by
the values obtained by densitometric analysis of the rela-
tive bands (bottom panels). As far as cathepsin D was
concerned, we found comparable amounts in cells
derived from primary or metastatic melanomas, whereas
the expression level of cathepsin L was variable and not
associated with malignancy. Conversely, the evaluation
of surface expression of cathepsins by flow cytometry
revealed that cathepsin B was higher in cell lines from
metastatic melanomas (MM1 and MM2 as representa-
tive cell lines) (Figures 1A and 1B, right panels) than in
cell lines derived from primary melanomas (PM1 and
PM2 as representative cell lines). These data were also
confirmed by extending the cytofluorimetric analysis to
a total of four different primary (PM1-PM4) and four
metastatic (MM1-MM4) melanoma cell lines (Figure
2A). In fact, a significantly higher expression of cathe-
psin B at the cell surface of metastatic melanoma cell
lines (left panels, p = 0.0087) was observed. By contrast,
both for cathepsin D and cathepsin L surface expression,
statistical analysis failed to reveal any significant differ-
ence between primary and metastatic melanoma cells
(p = 0.4513 and p = 0.2378, respectively), at least con-
sidering these eight cell lines.
The above results obtained with cathepsin B seem in
conflict with some literature data showing higher
amounts of cathepsin B mRNA or protein in malignant
tumors than in normal tissues or benign tumors [4,27].
On these bases, we performed, by quantitative real-time
RT-PCR, cathepsin B specific mRNA determination.
Being this protease a post-translational derivative of the
enzymatically inactive procathepsin B, we analyzed
the primary PM1 and the metastatic MM1 cell lines and
the autologous cell lines, PM2, from a primary human
melanoma, and MM2, from a supraclavicular lymph
node metastasis, for procathepsin B mRNA content. The
results, reported in Additional File 1, showed a signifi-
cantly higher content of procathepsin B transcripts in
the MM1 cell line, when compared to PM1 (+ 58%) and
in MM2 cell line versus PM2 cell line (+ 75%).
Cathepsin B activity in primary and metastatic human
melanoma cells
As clearly shown in Figure 2B (left panel), where results
obtained in two representative primary or metastatic
melanoma cell lines are shown, cathepsin B activity was
significantly higher in the growth medium of metastatic
than that of primary melanoma cells (p <0 . 0 1 ) .B yc o n -
trast, no significant differences in its activity were found
using specific fluorescent substrates for cathepsin D
(Figure 2B, central panel) or cathepsin L (Figure 2B,
right panel). Furthermore, the concentration of cystatin
C, an endogenous cathepsin B inhibitor, was found
higher in the growth medium of PM1 and PM2 in com-
parison with MM1 and MM2 cells (Figure 2C, p =
0.0017). As far as the intracellular content of cystatin C
was concerned (Figure 2D), flow cytometry analysis
revealed a modest, but significantly (p <0 . 0 1 )h i g h e r
amount of this physiological cathepsin B inhibitor in cell
lines from primary melanoma in comparison to those
from metastatic lesions. In Figure 2D two representative
cell lines from primary or metastatic melanoma lesions
are shown.
Analysis of the lysosomal compartment
We analyzed acidity and volume of the lysosomal com-
partment in four different melanoma cell lines both
from primary and metastatic lesions (Additional File 2A
and 2B). The results showed that the intracytoplasmic
vesicles were localized in invadopodia, as previously
described [28] (data not shown) and were significantly
more acidic in cells from metastatic melanomas with
respect to primary melanomas (p = 0.0083, Additional
File 2A, left and right panels, respectively). By contrast,
no significant difference was found in terms of lysoso-
mal volume (p = 0.2187, bottom panels in Additional
File 2B, left and right panels, respectively). We also
found that cells from metastatic melanomas (Additional
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Page 4 of 14Figure 1 Cathepsin B expression in cells from primary and metastatic human melanomas. Western blot analysis (left panels) of cathepsin
B, cathepsin D, cathepsin L and tubulin in the primary melanoma cell lines PM1 (A) and PM2 (B) and in the metastatic melanoma cell lines
MM1 (A) and MM2 (B). Quantitative flow cytometry analysis (right panels) of plasma membrane cathepsin B in PM1 (A) and PM2 (B) cell lines
and in MM1 (A) and MM2 (B) cell lines. The values of Western blot signals, reported in the bottom panels of (A) and (B), were obtained by
densitometric analysis and expressed as arbitrary units (a.u.). Numbers in the right panels of (A) and (B) represent the median fluorescence
values. In the right panels of (A) and (B) statistical analysis performed by non-parametric K/S test is reported.
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Page 5 of 14Figure 2 Cathepsin activity and cystatin C amount in primary and metastatic human melanoma cells.( A) Quantitative cytofluorimetric
analysis of plasma membrane cathepsin B, D and L in four different primary (white columns) and metastatic (black columns) melanoma cell
lines. Numbers represent the mean values among four different primary or metastatic melanoma cell lines analyzed. (B) Fluorimetric assays for
cathepsin B (black columns), cathepsin D (grey columns) and cathepsin L (white columns) activity in the cell medium of two representative
primary and metastatic melanoma cell lines. Results are reported as fluorescence units. (C) Concentration of cystatin C in the growth medium of
two representative primary and metastatic melanoma cell lines obtained by ELISA test. Results are reported as ng/ml. (*) p < 0.01 for PM cell
lines vs. MM cell lines by Student’s t-test. (D) Quantitative cytofluorimetric analysis of cystatin C intracellular content in two representative
primary (light grey histograms) and metastatic (deep grey histograms) melanoma cell lines. Numbers represent the median fluorescence values ±
SD among four independent measurements. Histograms from a representative experiment are shown.
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Page 6 of 14File 2C, right panel) were able to survive at low pH
values (5.5), whereas cells from primary lesions (left
panel) rapidly died when cultured under the same con-
ditions (primary vs. metastatic cells, p =2 . 2×1 0
-7).
These data are potentially interesting in this contest
because it has been reported that acidic pH can pro-
mote cancer dissemination by a mechanism involving
acidity-induced up-regulation of some proteolytic
enzymes such as metalloproteinase-2, cathepsin B,
cathepsin L and the pro-angiogenic factors VEGF-A and
IL-8 [29].
Cathepsin B and in vitro invasiveness: effects of chemical
and biological inhibitors
The relationship between in vitro invasiveness and
cathepsin B localization at the plasma membrane was
then analyzed in four different cell lines from both pri-
mary and metastatic human melanomas (Figure 3). All
the cell lines from metastatic melanomas showed a sig-
nificantly higher ability to cross through Matrigel than
those from primary lesions (Figure 3A, p = 0.0097). Syn-
thetic cysteinyl proteinase cathepsin B inhibitor CA-074,
but not synthetic aspartyl proteinase cathepsin D inhibi-
tor Pepstatin A and cathepsin L inhibitor, significantly
reduced the percentage of invading cells (Figure 3B, two
representative cell lines from primary and metastatic
melanoma are shown). In the same vein, we observed
that the presence of specific antibodies to cathepsin B in
the culture medium significantly decreased the percen-
tage of metastatic melanoma cells able to cross through
a basement membrane matrix, i.e. Matrigel (Figure 3C,
left panel). According to the results reported in Figure
3B, the presence of specific antibodies to cathepsin D or
cathepsin L in the culture medium did not significantly
reduce the percentage of cells migrating to the bottom
surface of the filter (Figure 3C, central and right panel,
respectively). Thus, on the bases of statistical analyses of
the data obtained in four different primary (PM1-PM4)
and metastatic (MM1-MM4) melanoma cell lines, we
can conclude that: i) inhibitors of cathepsin D and L, as
well as specific antibodies against both these proteases,
were ineffective in reducing invasion capability of both
primary and metastatic melanoma cell lines and that ii)
either the chemical inhibitor of cathepsin B, CA-074, or
specific anti-cathepsin B antibodies were able to signifi-
cantly prevent the in vitro invasiveness of metastatic
melanoma cell lines (Figure 3D).
Cathepsin B surface expression and in vitro invasiveness
Differential analysis of cathepsin B surface expression
performed in cells found above (non-invading) or
below (invading) the Matrigel-covered filter, clearly
demonstrated that invading cells (either from primary
or metastatic melanomas) showed a significantly higher
amount of cathepsin B at the cell surface (p < 0.01)
(results obtained in two representative cell lines from
primary and metastatic melanoma lesions are shown in
Figure 4A).
Interestingly, by selecting invading cells by repeated
passages through the Matrigel-covered filters, as illu-
strated in Figure 4B, we observed a progressive increase
of surface cathepsin B amount. In particular, we selected
MM4 cell line by four passages through the filter, seed-
ing separately at any passage on distinct transwell cul-
ture inserts the cells found above or those migrating
below the filter. Flow cytometry analysis of physical
parameters of these cells (after selection) also revealed
the appearance of a lower-sized cell sub-population (Fig-
ure 4C, R2 in central bottom panel), essentially negative
for surface cathepsin B determination (Figure 4C, left
bottom panel). Immunofluorescence microscopy analysis
confirmed the presence of several cathepsin B-negative
vesicles (Figure 4C, arrows in lower panels) possibly
budding from the cell surface (Figure 4B, arrow in the
lower left panel). The nature and biological significance
of these vesicles are not clear and should deserve more
exhaustive studies.
Cathepsins and in vitro invasiveness: effect of siRNA
Finally, according to the above results, cells knocked-
down for cathepsin B (Figure 5A, left panel) displayed a
significant (p < 0.01) reduction of their invasiveness
(Figure 5A, right panel). This was clearly evident in cell
lines derived from primary melanomas (PM1 and PM2)
and in those derived from metastatic lesions (MM1 and
MM2) as well.
On the bases of these results, we decided to contex-
tually transfect either MM1 (Figure 5B) or MM4 (Figure
5C) cells, the two metastatic melanoma cell lines tested
in in vivo experiments, with siRNA silencing cathepsin
B, D and L. Forty-eight hours after transfection, we eval-
uated by flow cytometry: (i) the percentage of trans-
fected cells (Figure 5B, MM1 cell line and Figure 5C,
MM4 cell line) and (ii) the expression level of cathepsin
B (second panel) cathepsin D (third panel) and cathe-
psin L (fourth panel). Knocked down cells were then
tested for their invasion capability. We found that cathe-
psin B silencing significantly reduced invasion capability
in both MM1 (Figure 5D, left panel) and MM4 (Figure
5D, right panel) cell line. By contrast, neither cathepsin
D nor cathepsin L silencing significantly affected the
invasiveness of these two metastatic cell lines.
In vivo efficacy of CA-074 on human melanoma
xenografts
T h eM M 1t h eh i g h l ym e t a s t a t i cM M 4h u m a nm e l a -
noma cells were used to investigate the antitumor activ-
ity of CA-074 administered systemically in mice. Indeed,
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Page 7 of 14Figure 3 Cathepsins and in vitro invasiveness: effect of chemical and biological inhibitors.( A)I n v a s i o nt e s to np r i m a r y( w h i t ec o l u m n s )
and metastatic (black columns) melanoma cell lines. (B) Invasion test on two representative cell lines from primary (white columns) and
metastatic (black columns) melanoma in the presence of CA-074 (left panel), Pepstatin A (central panel) or cathepsin L inhibitor (right panel).
Dotted lines represent the mean of the results obtained in primary melanoma cell lines, and dashed lines indicate the mean of the results
obtained in metastatic melanoma cell lines by using DMSO (vehicle of the cathepsin inhibitors). (C) Invasion test on two representative cell lines
from primary (white columns) and metastatic (black columns) melanoma in the absence or in the presence of specific antibodies against
cathepsin B (left panel), cathepsin D (central panel) or cathepsin L (right panel). Dotted lines represent the mean of the results obtained in
primary melanoma cell lines, and dashed lines indicate the mean of the results obtained in metastatic melanoma cell lines by using IgG1 as
positive control. (D) Histogram showing the results obtained from four different primary melanoma (white columns) or metastatic melanoma
(black columns) cell lines in the absence or in the presence of CA-074 or antibodies against cathepsin B. Data are reported as mean ± SD of the
percentage of invading cells. Student’s t-test indicates: p = 0.0097 for untreated MM cells vs. CA-074-treated MM cells and p = 0.0030 for
untreated MM cells vs. MM cells treated with anti-cathepsin B antibodies.
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Page 8 of 14Figure 4 Cathepsin B surface expression and in vitro invasiveness.( A) Quantitative flow cytometry analysis of plasma membrane cathepsin
B in PM1 and PM2 cell lines (empty histograms) and in MM1 and MM2 cell lines (full histograms) performed in cells found above (non invading)
or below (invading) the Matrigel covered filter. Numbers represent the median fluorescence values ± SD among three independent
measurements. Histograms from a representative experiment are shown. (B) Cytofluorimetric and fluorescence microscopy analyses of plasma
membrane cathepsin B in MM4 cell line during selection of invading cells by repeated passages through the Matrigel-covered filters. (C)
Cytofluorimetric analysis of plasma membrane cathepsin B in MM4 cells at the end of the selection after four passages through the Matrigel-
covered filters revealed the presence of a sub-population with reduced size (R2 region, bottom central panel) and negative to cathepsin B
(bottom left panel). In the bottom panels fluorescence microscopy micrographs showing cathepsin B-positive cells (corresponding to R1 region)
and cathepsin B-negative microvesicles, probably corresponding to the sub-population (R2 region) revealed by cytofluorimetric analysis. Arrows
indicate vesicles budding from (left picture) or near to (central picture) the cell. In the right panel a cluster of vesicles is shown.
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Page 9 of 14Figure 5 Cathepsins and in vitro invasiveness: effect of siRNA.( A) Western blot analysis of cathepsin B (left panels) and invasion test (right
panel) of cells knocked down for cathepsin B in two different primary (PM1 and PM2) and metastatic (MM1 and MM2) melanoma cell lines. The
values of Western blot signals, reported in the bottom left panels, were obtained by densitometric analysis and are expressed as arbitrary units
(a.u.). In vitro invasion test (right panel) in cells knocked down for cathepsin B showed a significant (p < 0.01) reduction of their invasion
capability. Data are reported as mean ± SD of the percentage of invading cells obtained in three independent experiments. Two representative
primary or metastatic melanoma cell lines are shown. (B and C) Flow cytometry evaluation of fluorescence in MM1 cells (B) or MM4 cells (C)
transfected with FITC-siRNA. The number in the left panel represents the percentage of FITC-positive cells (corresponding to transfected cells).
Cytofluorimetric evaluation, performed 48 h after transfection, of cathepsin B (second panel), D (third panel) or L (fourth panel) in MM1 (B) and
MM4 (C) cells transfected with non-silencing siRNA or with silencing siRNA. Numbers represent the median fluorescence intensity and indicate
the expression level of the cathepsins. A representative experiment among three is shown. (D) Invasion test of cells knocked down for
cathepsins in MM1 (left panel) and in MM4 (right panel) cell lines. (*) Indicates p < 0.01.
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Page 10 of 14the treatment of human melanoma-bearing mice signifi-
cantly reduced the growth of i.m.-injected tumors and
inhibited the number of artificial lung metastases. As
shown in Figure 6A, CA-074 injected in MM1 xeno-
grafts produced about 30% inhibition of tumor weights
when compared to control mice (p = 0.00025), as evalu-
ated at nadir of the effect. Such inhibition was accompa-
nied by a tumor growth delay of 7 days, significantly
different (p = 0.004) when compared to mice treated
with the vehicle alone (dimethyl sulfoxide, DMSO).
With the purpose to analyze the effect of CA-074 on
the metastatic potential of melanoma cells, mice were
injected i.v. with MM4 cells, a very aggressive human
melanoma cell line [26], being MM1 cells unable to
induce artificial lung metastases when injected i.v. Inter-
estingly, MM4 cells produced and secreted more than
Figure 6 Antitumor efficacy of CA-074 in human melanoma xenografts.( A) Tumor growth curves of mice bearing MM1 melanoma cells
and treated i.v. with vehicle alone (υ) or with CA-074 (s) for eight consecutive days, starting from day 6 after cell injection. Mean tumor weights
in mg ± SD are shown. (B) Mice were injected i.v. with MM4 cells and the day after, treated with CA-074 for eight consecutive days. At day 14
after cells injection, lungs were removed and fixed in Bouin’s solution to distinguish tumor nodules from lung tissue, and the number of
metastases was evaluated. The boxes show medians and 75th and 25th percentiles of the data, while the whiskers indicate the minimum and
maximum values. (C) Representative images of metastatic nodules in lungs from control and treated mice. Note the lower number of nodules in
the right picture.
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Page 11 of 1450-fold VEGF-A (226.6 ± 31.3 pg/ml) when compared
to MM1 cells (4.73 ± 1.9 pg/ml), a feature likely asso-
ciated with the high aggressiveness shown by the MM4
cell line. Extending this analysis to all cell lines consid-
ered here, we also found that the amount of VEGF-A in
the growth medium of the metastatic melanoma cells
(49.2 ± 83.7 pg/ml) resulted significantly higher (p =2 . 9
×1 0
-11) than that found in the primary melanoma cells
(0.5 ± 0.2 pg/ml). As far as the metastatic potential is
concerned, we found that mice treated with vehicle
alone showed a median number of 530 lung nodules
(range 310-600). Treatment with CA-074 significantly
reduced the number of nodules (median number 240,
range 178-310) (p = 0.0036) (Figure 6B). Representative
images of lungs removed from control or CA-074 trea-
ted mice are reported in Figure 6C.
Discussion
In the present work we investigated the role of cathe-
psin B, D and L in metastatic melanoma aggressiveness.
Unlike cathepsins D and L, cathepsin B appears to con-
tribute significantly to cell spreading and metastatic
potential. We also show for the first time that the speci-
fic cathepsin B inhibitor CA-074, as well as antibodies
directed against cathepsin B, was able per se, i.e. without
any further additional drug, to exert a powerful anti-
invasive activity by a mechanism that brings into play
the impairment of metastatic cell dissemination. This
was assessed both in vitro, i.e. in eight different cell
lines from primary and metastatic lesions, as well as in
vivo, i.e. in murine xenografts, where a decrease of
tumor weight and an increased tumor growth delay as
well as a significant reduction of artificial lung metas-
tases were detected after CA-074 administration.
The possible link between cathepsins and cancer and
the role of cathepsin B in metastatic potential was pos-
tulated since many years [30,31]. For instance, numerous
clinical studies have hypothesized a correlation between
extralysosomal cathepsin B expression and release with
neoplastic disease progression and clinical outcome [5].
However, in spite of the number of papers published in
the field, the mechanisms and the pathways involved are
still under investigation. Cathepsin B, either the mRNA
or the protein, was often detected in higher amount in
malignant tumors than in benign ones or in normal tis-
sues [27]. In addition, the intracellular trafficking of
cathepsin B appeared frequently altered in malignant
tumors [32], resulting in i) an increased secretion of
precursor and active forms of the enzyme [33], ii) its
redistribution from perinuclear lysosomes to peripheral
vesicles localized in invadopodes [34], and finally iii) its
association with the plasma membrane [35], where it
was found associated to the caveolae, via active K-RAS,
at least in colon cancer [36]. Some investigators
hypothesized a role for cathepsin B in the mechanisms
of invasion and metastasis [4]. In our experimental
model, in spite of the higher amount of cathepsin
B mRNA in metastatic melanoma cell lines in compari-
son to primary melanoma cell lines, we observed that
protein cathepsin B content was higher in primary mela-
noma than in metastatic melanoma cell lines. Thus, we
can hypothesize that this discrepancy could be due to a
major secretion of cathepsin B by metastatic cells.
According to this, our analyses performed at different
time points in invading cells after selections by repeated
passages through the Matrigel-covered filters, suggested
that plasma membrane localization of cathepsin B and
its extracellular activity, rather than its overall expres-
sion, had a major correlation with cell invasion
capabilities.
The pivotal and specific role of cathepsin B in meta-
static melanoma cells was also reinforced by the fact
that: i) differently from cathepsin B, the activity and the
expression of other two cathepsins analyzed here, cathe-
psin D and cathepsin L, were found essentially
unchanged in metastatic cells with respect to primary
melanoma cells. Furthermore, ii) specific inhibitors of
cathepsin D and cathepsin L, i.e. pepstatin A and cathe-
psin L inhibitor II, respectively, as well as their specific
siRNA, did not modify metastatic cell invasiveness in
vitro. Accordingly, cathepsin D was reported to be
involved in cellular transformation, being down-regu-
lated in melanoma cells with respect to melanocytes
[37], rather than in metastatic potential. As concerns
cathepsin L, this belongs to the cysteine protease family
and its expression was suggested to correlate with
increased invasion ability of tumor cells, e.g. of M14
murine melanoma cells in vitro [38]. At variance, we did
not find any significant association between the expres-
sion of this cathepsin and invasion capability. This
seems in accord with the hypothesis that high cathepsin
L concentrations are detectable in primary melanomas
with a poor prognosis [39].
As concerns cystatins, including cystatin C, they func-
tion as cysteine protease inhibitors. These are expressed
in numerous cell types and regulate a number of biolo-
gical processes, including tumor progression. Cystatins
are epigenetically silenced through DNA methylation-
dependent mechanisms in several forms of cancer and
they have been hypothesized to regulate promotion or
suppression of tumor growth, invasion, and metastasis
[40]. Our results indicated that high levels of cystatin C
could only be detected in the milieu of melanoma cells
from primary lesions. Hence, it cannot be excluded that
the low level of this physiological cathepsin inhibitor
found in the growth medium of metastatic melanoma
could be the result of its “exhaustion”,e . g .c o n s e q u e n t
to the attempt to counteract cathepsin activity.
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Page 12 of 14As a general rule, cathepsins are optimally active at an
acidic pH and extracellular pH is lower in many tumors
rather than in the corresponding normal tissue microen-
vironment. Cells cultured at acidic pH have been
reported to increase the secretion of proteinases and
proangiogenic factors and to enhance invasive and
angiogenic potential as well as the potential to develop
experimental metastases [29]. Our data indicated that,
conversely to cells from primary melanoma, metastatic
cells were able to survive at ac i d i cp H( s e eS u p p l e m e n -
tary Figure 1), also supporting the evidence that more
malignant tumors are able to grow and expand in an
acidic environment, as that ones produced under
hypoxic conditions [41]. Thus, a reappraisal of treatment
strategies involving deliberate tumor acidification to
improve the efficacy of chemotherapy should be consid-
ered. The possibility that cathepsins, including cathepsin
B, could play a key role in the formation of acidic
tumor microenvironment should also be taken into
account. A further point in this context concerns VEGF
secretion. It was suggested that acidic pH promotes
experimental metastasis by human melanoma cells via a
mechanism involving acidity-induced up-regulation of
proteolytic enzymes, including cathepsins, as well as up-
regulating pro-angiogenic f a c t o r ss u c ha sV E G F[ 2 9 ] .
Hence, considering their high production of VEGF, the
aggressive behavior of MM4 cells, once injected in mice,
it is not surprising and the effects obtained with CA-074
may also be partially referred to as its putative microen-
vironmental “buffering activity”.
The last important point regards the fact that either
chemical inhibitors, i.e. CA-074 and CA-074Me, or bio-
logical, i.e. antibodies directed against active cathepsin
B, as well as cathepsin B gene silencing with siRNA,
determine a significant impairment of cell aggressiveness
in terms of spreading ability. The block of cathepsin B
activity via antibody administration, unlike that of che-
mical compounds and siRNA, could impair metastatic
melanoma cell dissemination certainly exerting their
activity at extracellular level. Since the use of immu-
notherapeutic strategies recently acquired a clinical rele-
vance, specific in vivo studies with antibodies against
cathepsin B would be planned.
In conclusion, our paper suggests a role for cathepsin
B in tumor growth and in metastatic potential of human
melanoma. Inhibition of cathepsin B could possibly lead
to changes of tumor microenvironment, to a decreased
cell survival and spreading and, therefore, to the impair-
ment of metastatic seeding and onset. Further research
on melanoma, as well as on other tumor models, will
however be crucial to clarify these points before gener-
ating therapeutic strategies based on the use of available
or novel potential inhibitors of cathepsin B activity.
Additional material
Additional file 1: Relative quantification of procathepsin B gene
expression in primary and metastatic melanoma cells by real-time
quantitative PCR. The data indicate an increase in procathepsin B gene
expression in the metastatic MM1 and MM2 cell lines, when compared
with the primary melanomas PM1 and PM2, respectively. Values, average
of two experiments performed in triplicate ± SD, are normalized against
cyclophilin A. TAI, transcription activation index for procathepsin B.
Additional file 2: Analysis of the lysosomal compartment and cell
survival in acidic environment. Cytofluorimetric evaluation of lysosomal
acidity (A) and lysosomal volume (B) in four different primary (white
columns) and metastatic (black columns) human melanoma cell lines by
using LysoSensor-green and LysoTracker-green dye, respectively. Data are
reported as mean ± SD of the median fluorescence values among four
independent experiments. Statistical analysis by Student’s t-test indicates:
p = 0.0083 for lysosomal acidity and p = 0.1287 for lysosomal volume for
PM cell lines vs. MM cell lines. (C) Cell survival analysis at different pH
values of the growth medium was performed by Trypan blue test. Data
are reported as mean ± SD of the percentage of surviving cells obtained
in three separate experiments performed in triplicate. Statistical analysis
by Student’s t-test indicates: p =2 . 2×1 0
-7 for PM cell lines vs. MM cell
lines at pH 5.5.
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